Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 11/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701382 | 0.90 | EPHX2 (0.33) | MAPTARCSNK1DRAF1LMNA | |
| SCHEMBL2702583 | 0.89 | MAPT (0.36) | MAPTARCSNK1DRAF1LMNA | |
| SCHEMBL2702526 | 0.88 | MAPT (0.36) | MAPTARCSNK1DLMNAKDR | |
| SCHEMBL2702209 | 0.88 | MAPT (0.38) | MAPTARCSNK1DLMNAKDR | |
| SCHEMBL2702204 | 0.88 | MAPT (0.36) | MAPTARCSNK1DLMNAKDR | |
| SCHEMBL2701404 | 0.88 | MAPT (0.36) | MAPTARCSNK1DLMNAKDR | |
| SCHEMBL2703818 | 0.87 | MAPT (0.36) | MAPTARLMNACYP3A4BRAF | |
| SCHEMBL2702588 | 0.85 | MAPT (0.35) | MAPTARCSNK1DLMNAKDR | |
| SCHEMBL2703932 | 0.85 | RORC (0.35) | MAPTARCSNK1DRAF1LMNA | |
| SCHEMBL2702584 | 0.85 | AR (0.35) | MAPTARCSNK1DLMNAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | disclosed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2009-05-21 | — | — | US | disclosed |
| US-7465809-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | MAPT 2544/4885AR 1/4885CSNK1D 488/4885 |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | MAPT 2544/4885AR 1/4885CSNK1D 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.